14.78

4.34% -0.67

Syndax Pharmaceuticals Inc (SNDX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$15.45

Aprire:

$15.51

Volume 24 ore:

3.47M

Relative Volume:

1.53

Capitalizzazione di mercato:

$1.27B

Reddito:

$139.71M

Utile/perdita netta:

$-209.36M

Rapporto P/E:

-4.9932

EPS:

-2.96

Flusso di cassa netto:

$-160.60M

1 W Prestazione:

-4.95%

1M Prestazione:

-3.99%

6M Prestazione:

+12.65%

1 anno Prestazione:

-20.67%

Intervallo 1D:

$14.61

$15.77

Intervallo di 1 settimana:

$14.61

$15.94

Portata 52W:

$8.58

$22.50

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Nome

Syndax Pharmaceuticals Inc

Settore

Healthcare (1154)

Industria

Biotechnology (647)

Telefono

781-419-1400

Indirizzo

730 THIRD AVENUE, NEW YORK, MA

Dipendente

184

Cinguettio

@syndax

Prossima data di guadagno

2025-03-03

Ultimi documenti SEC

SNDX's Discussions on Twitter

Confronta SNDX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SNDX Syndax Pharmaceuticals Inc	14.78	1.33B	139.71M	-209.36M	-160.60M	-2.96
VRTX Vertex Pharmaceuticals Inc	383.12	99.25B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	591.99	63.46B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	453.56	59.27B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	736.76	44.78B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	334.40	37.75B	3.81B	-644.79M	-669.77M	-6.24

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-09-10	Ripresa	Stifel	Buy
2025-09-04	Ripresa	Guggenheim	Buy
2025-08-05	Reiterato	BTIG Research	Buy
2025-07-10	Iniziato	Goldman	Buy
2024-10-24	Iniziato	UBS	Buy
2024-06-28	Iniziato	Jefferies	Buy
2024-01-31	Downgrade	Scotiabank	Sector Outperform → Sector Perform
2023-12-22	Iniziato	Mizuho	Buy
2023-10-25	Iniziato	BofA Securities	Buy
2023-10-11	Iniziato	Goldman	Buy
2023-07-27	Iniziato	Scotiabank	Sector Outperform
2023-07-11	Iniziato	Guggenheim	Buy
2023-04-17	Ripresa	BTIG Research	Buy
2023-01-31	Iniziato	Stifel	Buy
2023-01-03	Iniziato	JP Morgan	Overweight
2022-07-28	Ripresa	B. Riley Securities	Buy
2022-04-11	Iniziato	H.C. Wainwright	Buy
2022-02-15	Iniziato	Goldman	Buy
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-05-25	Iniziato	Citigroup	Buy
2021-02-18	Iniziato	B. Riley Securities	Buy
2020-12-03	Iniziato	Stifel	Buy
2020-05-22	Aggiornamento	Citigroup	Neutral → Buy
2020-05-22	Downgrade	H.C. Wainwright	Buy → Neutral
2020-05-18	Downgrade	Citigroup	Buy → Neutral
2020-05-11	Reiterato	H.C. Wainwright	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Reiterato	H.C. Wainwright	Buy
2019-03-08	Reiterato	H.C. Wainwright	Buy
2019-01-04	Iniziato	Robert W. Baird	Outperform
2018-01-05	Iniziato	B. Riley FBR, Inc.	Buy
2017-03-16	Iniziato	FBR & Co.	Outperform
2017-03-02	Iniziato	Instinet	Buy
2016-10-07	Iniziato	Guggenheim	Buy
2016-03-28	Iniziato	Citigroup	Buy
2016-03-28	Iniziato	JMP Securities	Mkt Outperform
2016-03-28	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie

01:45 AM

Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research - MarketBeat

01:45 AM

Sep 19, 2025

Highs Report: What’s next for IRIDEX Corporation stockBreakout Watch & Daily Profit Focused Stock Screening - khodrobank.com

Sep 19, 2025

Update Recap: Can CZWI disrupt its industryEarnings Recap Report & Verified Entry Point Signals - khodrobank.com

Sep 19, 2025

BTIG Reiterates Buy Rating on SNDX with $56 Price Target | SNDX Stock News - GuruFocus

Sep 19, 2025

3 Potential Biotech Acquisition Targets - Seeking Alpha

Sep 19, 2025

SNDX: Revumenib Gains Key NCCN Recommendation for AML Treatment - GuruFocus

Sep 19, 2025

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - The Manila Times

Sep 19, 2025

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical - GlobeNewswire

Sep 19, 2025

Major Treatment Update: Syndax's Revuforj Secures NCCN Recognition for Rare Leukemia Mutation Therapy - Stock Titan

Sep 19, 2025

Sep 18, 2025

Breakouts Watch: Does Syndax Pharmaceuticals Inc. have strong fundamentalsPortfolio Value Report & Expert Curated Trade Ideas - khodrobank.com

Sep 18, 2025

Sep 17, 2025

Syndax resumed with Buy at Stifel on newly launched drugs - MSN

Sep 17, 2025

Syndax Pharmaceuticals’ SWOT analysis: biotech stock navigates AML market By Investing.com - Investing.com Canada

Sep 17, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4.8%Time to Sell? - MarketBeat

Sep 17, 2025

Syndax Pharmaceuticals’ SWOT analysis: biotech stock navigates AML market - Investing.com

Sep 17, 2025

Sep 16, 2025

Risk Hedge: Is Syndax Pharmaceuticals Inc stock a top performer YTDJuly 2025 Technicals & Stepwise Swing Trade Plans - خودرو بانک

Sep 16, 2025

Fundamentals Check: Can L3Harris Technologies Inc deliver consistent EPS growthWeekly Risk Summary & Stock Portfolio Risk Control - خودرو بانک

Sep 16, 2025

Earnings Recap: What are the future prospects of Syndax Pharmaceuticals IncTrade Analysis Report & Real-Time Market Sentiment Alerts - khodrobank.com

Sep 16, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by Stifel Nicolaus - MarketBeat

Sep 16, 2025

Sep 15, 2025

Exome Asset Management LLC Increases Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 15, 2025

213,159 Shares in Syndax Pharmaceuticals, Inc. $SNDX Acquired by Zimmer Partners LP - MarketBeat

Sep 15, 2025

Sep 13, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells $2,581,407.87 in Stock - MarketBeat

Sep 13, 2025

Sep 12, 2025

Polar Asset Management Partners Inc. Has $1.31 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Sep 12, 2025

Sep 11, 2025